Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Monday. The firm issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS opened at $0.02 on Monday. The company’s 50 day moving average is $0.20 and its 200-day moving average is $0.49. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49. The company has a market cap of $852,660.00, a P/E ratio of 0.00 and a beta of 1.55.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.